Brought to you by 
Endotis Pharma closes its Series B round
12 Feb 2008
Executive Summary
Endotis Pharma has raised €25mm ($36.2mm) through its Series B venture round. Wellcome Trust led the financing and was joined by Endeavour Vision, NIF SMBC Ventures, and returning backer Sofinnova Partners. The company will use the funds to continue developing compounds it in-licensed from Organon for arterial thrombosis and drug candidates it developed independently--EP37 for venous and arterial thrombosis and EP8000, which targets factors linked to angiogenesis, tumor growth, and metastasis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endotis Pharma closes its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice